BioSpace News Archive

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today announced that Chief Executive Officer Jonathan P. Mow will participate in a panel discussion during Cowen’s 42nd Annual Health Care Conference taking place virtually on Tuesday, March 8, 2022 from 12:50 pm – 1:50 pm ET.

BD, a leading global medical technology company, announced that it will virtually present at the Cowen 42nd Annual Health Care Conference via webcast.

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced recent company highlights and financial results from the fourth quarter and full year ended December 31, 2021.

Vapotherm, Inc., a global medical technology company focused on the development and commercialization of its innovative, comfortable, non-invasive technologies for respiratory support of patients with chronic or acute breathing disorders announced fourth quarter and fiscal year 2021 financial results.

Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted seven new employees options to purchase a total of 20,450 shares of the Company’s common stock at an exercise price per share of $30.01, which was the closing price on February 23, 2022, and restricted stock units to acquire a total of 10,225 shares of the Company’s common stock.

Reports full year 2021 revenue of $85.4 million, above pre-announced preliminary range Reiterates 2022 revenue outlook

Alimera Sciences, Inc. today announced financial results for the fourth quarter and full year 2021.

Pliant Therapeutics, Inc. announced that Bernard Coulie, M.D., Ph.D., Pliant’s President and Chief Executive Officer, will participate in the following conferences in March.

HiberCell has initiated a Phase 1a/b clinical trial of HC-7366, a first-in-class selective, orally bioavailable modulator of General Control Nonderepressible 2 (GNC2) for the treatment of patients with advanced solid tumors.

Genus plc is pleased to announce that PIC has entered into definitive agreements with Olymel LP, a leader in the Canadian agrifood industry, for provision of genetic products and services in connection with the Olymel’s AlphaGene porcine genetic improvement program.